ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
129.320,96
0,33%
S&P 500
5.631,22
0,28%
US Dollar vs BRL
5,4485
0,00%
Bitcoin
63.648,07
-1,85%
Brent Oil
83,975
-0,43%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Champions Oncology Inc (CSBR)

  7. Champions Oncology Inc (CSBR) Notícias

CSBR

Champions Oncology (CSBR)

Champions Oncology Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:CSBR
DataHoraFonteTítuloCódigoCompanhia
26/09/201709:30PR Newswire (US)Champions Oncology announces $2 million award from the National Cancer Institute (NCI) to develop and evaluate prostate cance...NASDAQ:CSBRChampions Oncology Inc
18/09/201710:15PR Newswire (US)Champions Oncology announces publication highlighting clinical correlation between patient-derived xenograft (PDX) model resp...NASDAQ:CSBRChampions Oncology Inc
14/09/201718:24Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:CSBRChampions Oncology Inc
14/09/201717:34Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CSBRChampions Oncology Inc
14/09/201717:30PR Newswire (US)Champions Oncology Reports Record Quarterly Revenue of $5 MillionNASDAQ:CSBRChampions Oncology Inc
07/09/201718:00PR Newswire (US)Champions Oncology to Announce First Quarter Financial Results on Thursday, September 14, 2017NASDAQ:CSBRChampions Oncology Inc
31/08/201718:31Edgar (US Regulatory)Revised Proxy Soliciting Materials (definitive) (defr14a)NASDAQ:CSBRChampions Oncology Inc
28/08/201718:21Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:CSBRChampions Oncology Inc
21/08/201709:30PR Newswire (US)Champions Oncology Announces Strategic Collaboration with AstraZeneca to Develop Unique Cohorts of Patient-Derived Xenograft ...NASDAQ:CSBRChampions Oncology Inc
18/08/201709:30PR Newswire (US)Champions Oncology Announces Research Collaboration with The Addario Lung Cancer Medical Institute to Develop Unique Cohort o...NASDAQ:CSBRChampions Oncology Inc
15/08/201705:57PR Newswire (US)The Addario Lung Cancer Medical Institute, Champions Oncology and Motivated Patients Announce a Research Collaboration and La...NASDAQ:CSBRChampions Oncology Inc
08/08/201715:59Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:CSBRChampions Oncology Inc
28/07/201717:04Edgar (US Regulatory)Annual Report (10-k)NASDAQ:CSBRChampions Oncology Inc
27/07/201717:01PR Newswire (US)Champions Oncology Reports 38% Revenue Growth for Fiscal Year Ended April 30, 2017NASDAQ:CSBRChampions Oncology Inc
17/07/201709:30PR Newswire (US)Champions Oncology Schedules Fourth Quarter and Fiscal Year 2017 Earnings CallNASDAQ:CSBRChampions Oncology Inc
16/03/201717:01PR Newswire (US)Champions Oncology Reports 40% Revenue GrowthNASDAQ:CSBRChampions Oncology Inc
16/03/201710:00PR Newswire (US)Champions Oncology Announces Plan to Open New Lab Facility in Rockville, MarylandNASDAQ:CSBRChampions Oncology Inc
10/03/201713:05Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CSBRChampions Oncology Inc
07/03/201710:00PR Newswire (US)Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 16, 2017NASDAQ:CSBRChampions Oncology Inc
16/02/201712:36PR Newswire (US)Champions Oncology Announces New Collection of Patient-Derived Xenograft (PDX) Models Available for Translational ResearchNASDAQ:CSBRChampions Oncology Inc
19/01/201713:38PR Newswire (US)Champions Oncology Retains Hayden IR to Execute Comprehensive Investor Relations ProgramNASDAQ:CSBRChampions Oncology Inc
13/01/201712:48Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:CSBRChampions Oncology Inc
13/12/201616:22Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:CSBRChampions Oncology Inc
29/11/201619:15PR Newswire (US)Champions Oncology Reports 50% Revenue Growth, Accelerated Progress on Path to Profitability and Future Role Changes of the S...NASDAQ:CSBRChampions Oncology Inc
23/11/201613:20PR Newswire (US)Champions Oncology to Announce Second Quarter Financial Results on Tuesday, November 29, 2016NASDAQ:CSBRChampions Oncology Inc
17/11/201619:05PR Newswire (US)Champions Oncology Signs $2 million ContractNASDAQ:CSBRChampions Oncology Inc
16/11/201611:58Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:CSBRChampions Oncology Inc
15/11/201617:27Business WireSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Delaware Law by Certain O...NASDAQ:CSBRChampions Oncology Inc
21/09/201615:25Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:CSBRChampions Oncology Inc
09/09/201609:15PR Newswire (US)Champions Oncology Beats Revenue Guidance for Quarter; Reaffirms Full Year Guidance of 43 - 60% Revenue GrowthNASDAQ:CSBRChampions Oncology Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:CSBR

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
TELB4
TELEBRAS PN
BOV
MGLU3
MAGAZINE LUIZA ON
BOV
INBR32
Inter &
BOV
GFSA3
GAFISA ON
BOV
AZEV4
AZEVEDO PN
BOV
AMER3
Americanas ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados